HumanMDR1and Mousemdr1aP-Glycoprotein Alter the Cellular Retention and Disposition of Erythromycin, but Not of Retinoic Acid or Benzo(a)pyrene
- 1 February 1998
- journal article
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 350 (2), 340-347
- https://doi.org/10.1006/abbi.1997.0537
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*Clinical Pharmacology & Therapeutics, 1997
- Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestineProceedings of the National Academy of Sciences, 1997
- Interaction of structurally diverse pesticides with thehuman MDR1 gene product P-glycoproteinToxicology and Applied Pharmacology, 1996
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.Proceedings of the National Academy of Sciences, 1996
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Journal of Clinical Investigation, 1995
- Phenotypic variability in induction of p‐glycoprotein mrna by aromatic hydrocarbons in primary human hepatocytesMolecular Carcinogenesis, 1995
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsCell, 1994
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proceedings of the National Academy of Sciences, 1987
- Potentiation of vincristine by vitamin A against drug-resistant mouse leukaemia cellsBritish Journal of Cancer, 1987